Safety and cost-effectiveness of single dose dispensing of bevacizumab for various retinal pathologies in developing countries

Velpandian, T.; Sharma, C.; Pharm, M.; Garg, S. P.; Mandal, S.; Ghose, S.
November 2007
Indian Journal of Ophthalmology;Nov2007, Vol. 55 Issue 6, p488
Academic Journal
No abstract available.


Related Articles

  • Adverse events associated with intraocular injections of bevacizumab in eyes with neovascular glaucoma. Higashide, Tomomi; Murotani, Eiji; Saito, Yoshiaki; Ohkubo, Shinji; Sugiyama, Kazuhisa // Graefe's Archive of Clinical & Experimental Ophthalmology;Apr2012, Vol. 250 Issue 4, p603 

    Background: Bevacizumab, a humanized monoclonal antibody against vascular endothelial growth factor (VEGF), has been reported to cause rapid regression of anterior segment neovascularization in eyes with neovascular glaucoma when administered intraocularly. Several studies have reported the...

  • Bevacizumab.  // Reactions Weekly;9/22/2007, Issue 1170, p11 

    The article describes the cases of 12 elderly patients, 10 women and 2 men, aged between 67-90 years, who developed retinal pigment epithelial (RPE) tears after receiving bevacizumab for neovascular age-related macular degeneration. All the patients received bevacizumab injections in varying...

  • Management of retinopathy of prematurity. Fleck, Brian William // Archives of Disease in Childhood -- Fetal & Neonatal Edition;Sep2013, Vol. 98 Issue 5, pF454 

    While current management of retinopathy of prematurity (ROP) is well evidenced, the recent Neonatal Oxygenation Prospective Meta-analysis (NeoPROM) oxygen therapy trials, and the Bevacizumab Eliminates the Angiogenic Threat of Retinopathy of Prematurity (BEAT-ROP) trial of intravitreal injection...

  • Preclinical aspects of anti-VEGF agents for the treatment of wet AMD: ranibizumab and bevacizumab. Meyer, C. H.; Holz, F. G. // Eye;Jun2011, Vol. 25 Issue 6, p661 

    Three anti-vascular endothelial growth factor (VEGF) therapies are currently used for the treatment of patients with wet age-related macular degeneration (AMD): pegaptanib, ranibizumab, and bevacizumab. Ranibizumab is an antibody fragment approved for the treatment of wet AMD. Bevacizumab is a...

  • Bevacizumab.  // Reactions Weekly;5/24/2008, Issue 1203, p13 

    The article describes several cases of elderly patients who developed retinal pigment epithelial tears after receiving intravitreal bevacizumab injections for exudative age-related macular degeneration. Particular focus is given to their dosing regimen. A decrease in visual acuity was observed...

  • Bevacizumab.  // Reactions Weekly;7/17/2010, Issue 1310, p14 

    The article describes the case of a male infant who developed retinal detachment after receiving bevacizumab for retinopathy of prematurity.

  • Bevacizumab.  // Reactions Weekly;1/8/2011, Issue 1333, p13 

    The article describes five cases of retinal vascular occlusion that developed in five patients during treatment with intravitreal bevacizumab.

  • Bevacizumab.  // Reactions Weekly;Jun2015, Vol. 1555 Issue 1, p38 

    The article presents a case study of a 35-week old premature boy, who developed retinal detachment following administration of bevacizumab.

  • 2008: The year of watchful waiting in retina. Charters, Lynda // Ophthalmology Times;12/15/2008, Vol. 33 Issue 24, p18 

    The article focuses on the various anticipations of retinal specialists concerning the results of a number of ongoing trials of drugs for various retinal pathologies for the year 2008 in the U.S. It says that medical retina and the anti-vascular endothelial growth factor therapies were center...

  • Bevacizumab vs. Ranibizumab in Preserving or Improving Vision in Patients with Wet, Age-Related Macular Degeneration: A Cost-effectiveness Review. Nwanze, Chukwuemeka C.; Akinwale, Abumere; Adelman, Ron A. // Clinical Medicine Insights: Therapeutics;2012, Issue 4, p29 

    Objective: To evaluate the cost-effectiveness of monthly and as-needed dosing protocols using ranibizumab or bevacizumab for the treatment of neovascular age-related macular degeneration (AMD), when the treatment costs of severe ocular and systemic adverse events are considered. Methods: A...


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics